Treatment with omalizumab offers modest protection from allergic reactions to individuals with multiple food allergies, and ...

Please provide your email address to receive an email when new articles are posted on . Data came from the FDA Adverse Event Reporting System from 2004 to 2024. Omalizumab had significant associations ...

Researchers compared the effectiveness of 3 biologics for moderate to severe asthma in an observational study and found superior improvement with dupilumab. Dupilumab was associated with higher ...

Please provide your email address to receive an email when new articles are posted on . Omalizumab may effectively treat food allergy symptoms in patients with alpha-gal syndrome, according to ...

In patients with chronic spontaneous urticaria, biomarkers such as a positive chronic urticaria index and low blood histamine ...

JERSEY CITY, N.J., March 9, 2025 /PRNewswire/ -- Celltrion today announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO ® (omalizumab-igec) as the first and only biosimilar designated ...

Among those who received omalizumab, a 1044 mg dose of 1, 2, and 3 allergenic foods had no adverse effect in 80%, 69%, and 47% of participants, respectively. Omalizumab for 16 weeks increased the ...

Food allergies are common and are associated with substantial morbidity; the only approved treatment is oral immunotherapy for peanut allergy. In this trial, we assessed whether omalizumab, a ...

This is a case study of a male patient with Fabry disease who presented with severe anaphylaxis following re-initiation of full-strength treatment with intravenous agalsidase beta (Fabrazyme). A ...

The FDA approved omalizumab-igec (Omlyclo) as the first biosimilar for omalizumab (Xolair) and the first for any respiratory condition in the U.S., drugmaker Celltrion announced Monday. The ...

Researchers led by the Institut Pasteur, Université Paris, have developed a vaccine that elicits anti-Immunoglobulin E ...